India, April 30 -- Share of Ernexa Therapeutics Inc. (ERNA) is down by 20% after the company announced a 1-for-25 reverse stock split of its common stock, effective May 4, 2026.
The move is intended to help the company regain compliance with Nasdaq' $1.00 minimum bid price requirement, a key condition for continued listing on the exchange.
Ernexa, which is developing engineered stem-cell therapies for advanced cancers and autoimmune diseases, said the stock will begin trading on a split-adjusted basis when the market opens on May 4, 2026, under the existing trading symbol "ERNA."
Following the split, the company expects its outstanding share count to decrease from 29.15 million to approximately 1.17 million, with no fractional shares iss...